The Institute for Clinical and Economic Review (ICER) produces reports, known as “cost-effectiveness analyses” or “value assessments” on how much it thinks new drugs should cost. ICER metrics value treating young individuals in good health as more cost-effective than treating older adults (65 and older) or people with disabilities. Learn more at ICERfacts.org